Primary source: European Medicines Agency (EMA)
Revised technical validation rules for eCTD v4.0 submissions, requiring compliance for PSURs, RMPs, and other related filings.
These updates are critical for ensuring the accuracy and compliance of electronic submissions, impacting regulatory processes across the EU.
All electronic PV submissions must undergo new validation checks in accordance with the updated criteria to ensure compliance and accuracy.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
New validation checks and bug fixes for v4.0 electronic submissions.
Requires technical alignment of electronic PV submissions (PSUR/RMP) with the updated validation criteria.
All electronic PV submissions must undergo new validation checks in accordance with the updated criteria to ensure compliance and accuracy.
The European Medicines Agency has revised the technical validation criteria for eCTD v4.0 submissions, introducing new validation checks and bug fixes. This change necessitates that electronic pharmacovigilance submissions, including Periodic Safety Update Reports (PSURs) and Risk Management Plans (RMPs), align with the updated validation criteria.
What changed: Revised technical validation rules for eCTD v4.0 submissions, requiring compliance for PSURs, RMPs, and other related filings.
Why it matters: These updates are critical for ensuring the accuracy and compliance of electronic submissions, impacting regulatory processes across the EU.
Practical implication: All electronic PV submissions must undergo new validation checks in accordance with the updated criteria to ensure compliance and accuracy.
Published from the Firecrawl policy change extraction pipeline.
Monitor and evaluate the drug misuse trends and health impacts associated with ketamine, focusing on the increase in seizures as part of public health and law enforcement strategies.
Implement the updated product information by November 5, 2026, ensuring that all labeling and documentation includes the new warnings and risk profiles.
Implement new labeling requirements for choline salicylate products by November 5, 2026, including specific warnings as outlined.
The marketing authorization holder must submit amended product information reflecting the new safety guidelines by October 9, 2026, with translations due by August 10, 2026.
